Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html

Study Counts

Type Study_count
Total_Studies 109
interventional 92
Observational 14
Registry 3

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 44
Drug|Radiation 6
Drug|Other 5
Biological|Drug 4
Biological 3
Drug|placebo 3
Drug|Procedure 3
Biological|Drug|Other 2
Drug|Other|Radiation 2
Drug|placebo|Radiation 2
Behavioral|Other|Procedure 1
Biological|Drug|Genetic|Other 1
Biological|Drug|Other|placebo 1
Biological|Drug|placebo 1
Biological|Drug|Radiation 1
Biological|Other|Procedure|Radiation 1
Biological|Procedure 1
Biological|Radiation 1
Diagnostic Test 1
Diagnostic Test|Drug 1
Dietary Supplement 1
Drug|Genetic|Other|Procedure 1
Drug|Other|placebo 1
Drug|Other|placebo|Radiation 1
Genetic 1
Genetic|placebo 1
Other 1
Radiation 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 48
China 13
NA 5
Korea, Republic of 4
Germany 3
Canada 2
Australia|Canada|China|France|Germany|Hong Kong|Ireland|Korea, Republic of|Norway|Singapore|Spain|Sweden|Taiwan|United Kingdom 1
Belarus|Hungary|Poland|Russian Federation|Ukraine 1
France 1
France|Germany 1
India 1
Latvia|Turkey|Hungary 1
Poland|Ukraine 1
United Kingdom 1
United States|Australia|Canada|Germany|Italy|Poland|Russian Federation|Spain 1
United States|Bulgaria|Poland|Romania|Russian Federation|Ukraine 1
United States|Canada|France 1
United States|Canada|Israel 1
United States|Hong Kong|Japan|Korea, Republic of|Taiwan 1
United States|Hong Kong|Japan|Singapore|Taiwan 1
United States|Mexico 1
United States|Norway|Spain|United Kingdom 1
United States|Puerto Rico 1

Sites per Study

Site_count Study_Count
1 54
2 2
3 5
4 3
5 2
6 3
7 3
11 1
13 1
16 1
21 1
23 2
24 1
30 1
41 1
43 1
62 1
63 1
93 1
96 1
224 1
235 1
798 1
931 1
938 1
1498 1

Phase

Phase Study_Count
Phase 2 47
Phase 3 13
Phase 1/Phase 2 11
Phase 1 9
N/A 8
Phase 2/Phase 3 2
Early Phase 1 1
Phase 4 1

Number of Arms

Number_of_Arms Count_of_Studies
1 39
2 38
3 3
4 5
6 1
7 1
11 1
NA 4

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 10 4.00 2.00000 21.00000 5.0000 300.0 23.0000 62
1st Qu. 10 82.25 15.00000 24.50000 43.0000 435.5 270.0000 62
Median 10 220.50 17.00000 46.00000 80.0000 571.0 503.0000 62
Mean 10 1663.50 23.11111 50.54545 114.8723 571.0 549.9231 62
3rd Qu. 10 1828.50 30.00000 54.50000 121.0000 706.5 756.0000 62
Max. 10 8300.00 60.00000 162.00000 818.0000 842.0 1333.0000 62

Trial Group Type

group_type Group_Count
Experimental 119
Active Comparator 28
Placebo Comparator 8
Other 7
No Intervention 6
NA 4

Intervention Model

intervention_model Study_Count
Parallel Assignment 46
Single Group Assignment 42
Sequential Assignment 2
NA 2

Primary Purpose

primary_purpose Study_Count
Treatment 86
Health Services Research 2
Diagnostic 1
Other 1
Prevention 1
Screening 1

Observational Studies

Studies by Country

Country Study_Count
China 3
United States 3
France 1
Hungary 1
Italy 1
Korea, Republic of 1
NA 1
Netherlands 1
Taiwan 1
United Kingdom 1

Sites per Study

Site_count Study_Count
1 10
2 1
10 1
14 1
16 1

Enrollment Metrics

Measure Observational
Min 13.0000
1st Qu 63.5000
Median 200.0000
Mean 333.2857
3rd Qu 525.7500
Max 1100.0000

Observation Model

observational_model Study_Count
Cohort 7
Case-Only 6
Other 1

Time Perspective

time_perspective Study_Count
Prospective 8
Retrospective 6

Registries

Studies by Country

Country Study_Count
NA 1
Singapore 1
United States 1

Sites per Study

Site_count Study_Count
1 2
2 1

Enrollment Metrics

Measure Registries
Min 100
1st Qu 172
Median 244
Mean 1448
3rd Qu 2122
Max 4000

Registry Model

observational_model Study_Count
Cohort 3

Time Perspective

time_perspective Study_Count
Prospective 3

Follow-up

target_duration Study_Count
3 Years 1
5 Years 1
99 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT01218516 A Safety and Efficacy Study of Farletuzumab in Subjects With Adenocarcinoma of the Lung https://ClinicalTrials.gov/show/NCT01218516 Completed Morphotek 2012-12-31
NCT03380468 Adjuvant Chemotherapy for High Post-operative Recurrence Risk Stage pI Lung Adenocarcinoma https://ClinicalTrials.gov/show/NCT03380468 Recruiting Fudan University 2021-01-01
NCT03298763 Targeted Stem Cells Expressing TRAIL as a Therapy for Lung Cancer https://ClinicalTrials.gov/show/NCT03298763 Recruiting University College, London 2023-09-01
NCT03184571 Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC https://ClinicalTrials.gov/show/NCT03184571 Recruiting BerGenBio ASA 2022-12-31
NCT03110978 Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT03110978 Recruiting M.D. Anderson Cancer Center 2022-06-30
NCT03076164 A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib https://ClinicalTrials.gov/show/NCT03076164 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-03-31
NCT03054298 CAR T Cells in Mesothelin Expressing Cancers https://ClinicalTrials.gov/show/NCT03054298 Recruiting University of Pennsylvania 2021-03-31
NCT03044626 Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC https://ClinicalTrials.gov/show/NCT03044626 Active, not recruiting AIO-Studien-gGmbH 2020-12-31
NCT02979821 Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001) https://ClinicalTrials.gov/show/NCT02979821 Completed Korean Association for the Study of Targeted Therapy 2017-12-31
NCT02971176 Low-dose Protocol for Computed Tomography-guided Lung Biopsy https://ClinicalTrials.gov/show/NCT02971176 Completed Xuzhou Central Hospital 2019-05-31
NCT02929693 Clinical Study of YYJD Decoction Combined With Gefitinib in Advanced Pulmonary Adenocarcinoma https://ClinicalTrials.gov/show/NCT02929693 Enrolling by invitation Shanghai University of Traditional Chinese Medicine 2019-06-30
NCT02893332 Stereotactic Body Radiation Therapy (SBRT) in Newly Diagnosed Advanced Staged Lung Adenocarcinoma (Sindas) https://ClinicalTrials.gov/show/NCT02893332 Recruiting Sichuan Provincial People’s Hospital 2019-12-31
NCT02889692 Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma https://ClinicalTrials.gov/show/NCT02889692 Completed Shanghai University of Traditional Chinese Medicine 2016-12-30
NCT02759835 Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib https://ClinicalTrials.gov/show/NCT02759835 Active, not recruiting National Institutes of Health Clinical Center (CC) 2021-02-01
NCT02679443 Vitamin Supplementation in NSCLC Patients on Pemetrexed Based Chemotherapy https://ClinicalTrials.gov/show/NCT02679443 Completed Postgraduate Institute of Medical Education and Research 2016-12-31
NCT02668393 Nintedanib and Weekly Docetaxel in Lung Adenocarcinoma https://ClinicalTrials.gov/show/NCT02668393 Completed Boehringer Ingelheim 2019-11-27
NCT02834013 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors https://ClinicalTrials.gov/show/NCT02834013 Recruiting National Cancer Institute (NCI) 2021-08-31
NCT02194738 Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) https://ClinicalTrials.gov/show/NCT02194738 Recruiting National Cancer Institute (NCI) 2021-09-28
NCT03391869 Phase III Trial of (LCT) After Nivolumab and Ipilimumab https://ClinicalTrials.gov/show/NCT03391869 Recruiting M.D. Anderson Cancer Center 2022-12-31
NCT02535325 Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT02535325 Active, not recruiting National Cancer Institute (NCI) 2021-01-01
NCT02513667 Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma https://ClinicalTrials.gov/show/NCT02513667 Active, not recruiting University of Texas Southwestern Medical Center 2020-08-31
NCT02493582 The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR https://ClinicalTrials.gov/show/NCT02493582 Active, not recruiting The First People’s Hospital of Changzhou 2030-07-31
NCT02450591 Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations https://ClinicalTrials.gov/show/NCT02450591 Completed Memorial Sloan Kettering Cancer Center 2017-12-11
NCT02303977 Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based Chemotherapy https://ClinicalTrials.gov/show/NCT02303977 Active, not recruiting Abramson Cancer Center of the University of Pennsylvania 2020-12-31
NCT02281708 Multicenter Randomized Controlled Trial Adjuvant Chemotherapy vs Observation in pStage Ib Lung Adenocarcinoma https://ClinicalTrials.gov/show/NCT02281708 Recruiting Seoul National University Hospital 2018-09-30
NCT02276027 A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT02276027 Completed Novartis 2019-10-15
NCT02186847 Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT02186847 Active, not recruiting NRG Oncology 2019-04-16
NCT02155465 Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib https://ClinicalTrials.gov/show/NCT02155465 Completed Memorial Sloan Kettering Cancer Center 2017-10-31
NCT02120807 Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas https://ClinicalTrials.gov/show/NCT02120807 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-04-30
NCT01294306 MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy https://ClinicalTrials.gov/show/NCT01294306 Completed National Cancer Institute (NCI) 2015-08-31
NCT02737774 Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation https://ClinicalTrials.gov/show/NCT02737774 Active, not recruiting Henan Cancer Hospital 2019-10-25
NCT03351842 Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20% https://ClinicalTrials.gov/show/NCT03351842 Recruiting Shanghai Pulmonary Hospital, Shanghai, China 2019-09-01
NCT01946100 Treatment of Multifocal Lung Adenocarcinoma https://ClinicalTrials.gov/show/NCT01946100 Active, not recruiting Mayo Clinic 2020-10-31
NCT01935336 Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers https://ClinicalTrials.gov/show/NCT01935336 Active, not recruiting University of Colorado, Denver 2017-01-31
NCT01877083 Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung https://ClinicalTrials.gov/show/NCT01877083 Completed Eisai Inc. 2016-02-03
NCT01851096 Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma https://ClinicalTrials.gov/show/NCT01851096 Completed Esanex Inc. 2015-10-31
NCT01829217 Sunitinib in Never-Smokers With Lung Adenocarcinoma https://ClinicalTrials.gov/show/NCT01829217 Completed Dana-Farber Cancer Institute 2017-08-31
NCT01737502 Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT01737502 Recruiting Mayo Clinic 2020-08-21
NCT01726296 Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care https://ClinicalTrials.gov/show/NCT01726296 Completed Fox Chase Cancer Center 2015-07-31
NCT01719536 Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients https://ClinicalTrials.gov/show/NCT01719536 Completed Betta Pharmaceuticals Co., Ltd. 2016-09-30
NCT01668823 Photodynamic Therapy in Treating Patients With Lung Cancer https://ClinicalTrials.gov/show/NCT01668823 Completed Roswell Park Cancer Institute 2013-06-30
NCT01588704 Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab in Unresectable, Locally Advanced Lung Adenocarcinoma https://ClinicalTrials.gov/show/NCT01588704 Completed Sun Yat-sen University 2014-01-31
NCT01565538 Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma https://ClinicalTrials.gov/show/NCT01565538 Completed Sun Yat-sen University 2012-05-31
NCT01561456 Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung https://ClinicalTrials.gov/show/NCT01561456 Completed Axelar AB 2013-12-31
NCT01557959 Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT01557959 Completed Wake Forest University Health Sciences 2011-02-28
NCT01466660 LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung https://ClinicalTrials.gov/show/NCT01466660 Completed Boehringer Ingelheim 2016-04-08
NCT01386385 Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery https://ClinicalTrials.gov/show/NCT01386385 Active, not recruiting National Cancer Institute (NCI) 2021-01-02
NCT01362790 SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma https://ClinicalTrials.gov/show/NCT01362790 Completed National Institutes of Health Clinical Center (CC) 2016-08-03
NCT01345851 Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery https://ClinicalTrials.gov/show/NCT01345851 Active, not recruiting Jonsson Comprehensive Cancer Center 2020-12-31
NCT04344795 Phase 1a/1b Study of TPST-1495 Alone and With Pembrolizumab in Subjects With Solid Tumors https://ClinicalTrials.gov/show/NCT04344795 Recruiting Tempest Therapeutics 2021-08-31
NCT04046614 Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology https://ClinicalTrials.gov/show/NCT04046614 Recruiting AIO-Studien-gGmbH 2021-07-03
NCT04027946 LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC) https://ClinicalTrials.gov/show/NCT04027946 Recruiting National Institutes of Health Clinical Center (CC) 2021-04-30
NCT03905317 Bevacizumab and Radiotherapy for Oligometastasis of Lung Adenocarcinoma With Negative Driver Gene https://ClinicalTrials.gov/show/NCT03905317 Recruiting Sun Yat-sen University 2022-02-28
NCT03904563 Bevacizumab After Chemoradiotherapy For Locally Advanced Lung Adenocarcinoma https://ClinicalTrials.gov/show/NCT03904563 Recruiting Sun Yat-sen University 2021-12-31
NCT03891173 A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma https://ClinicalTrials.gov/show/NCT03891173 Recruiting Helix BioPharma Corporation 2021-06-30
NCT03704870 Outcomes Following Omission of Daily Routine Chest Radiographs Following Pulmonary Resection https://ClinicalTrials.gov/show/NCT03704870 Completed University Health Network, Toronto 2019-12-31
NCT03696212 Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma https://ClinicalTrials.gov/show/NCT03696212 Recruiting Arrys Therapeutics 2020-09-30
NCT03676192 To Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT03676192 Recruiting Celltrion 2021-01-31
NCT03662477 Effect of NK Cell Immunotherapy on Advanced Lung Adenocarcinoma Adenocarcinoma With EGFR Mutation https://ClinicalTrials.gov/show/NCT03662477 Recruiting Shenzhen Fifth People’s Hospital 2019-12-20
NCT03544814 EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression https://ClinicalTrials.gov/show/NCT03544814 Completed Shanghai Chest Hospital 2017-06-01
NCT03476681 QUILT-3.017: Study of NEO-201 in Solid Tumors https://ClinicalTrials.gov/show/NCT03476681 Recruiting Precision Biologics, Inc 2020-10-15
NCT01259089 Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT01259089 Completed Northwestern University 2013-06-04
NCT01051934 A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma https://ClinicalTrials.gov/show/NCT01051934 Completed National Institutes of Health Clinical Center (CC) 2011-09-28
NCT01003899 A Phase II Trial of Afatinib(BIBW 2992) in Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor[EGFR] https://ClinicalTrials.gov/show/NCT01003899 Completed Boehringer Ingelheim 2011-11-30
NCT00966914 Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin https://ClinicalTrials.gov/show/NCT00966914 Completed BioNumerik Pharmaceuticals, Inc. 2013-04-30
NCT00946712 S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT00946712 Active, not recruiting Southwest Oncology Group 2017-08-31
NCT03845296 Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) https://ClinicalTrials.gov/show/NCT03845296 Recruiting Southwest Oncology Group 2021-07-01
NCT03199651 Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT03199651 Recruiting Ohio State University Comprehensive Cancer Center 2020-06-30
NCT03345810 Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION) https://ClinicalTrials.gov/show/NCT03345810 Recruiting AIO-Studien-gGmbH 2022-06-30
NCT01609543 A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations https://ClinicalTrials.gov/show/NCT01609543 Completed Hoffmann-La Roche 2015-01-31
NCT01578668 Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases https://ClinicalTrials.gov/show/NCT01578668 Completed Guangzhou Medical University 2015-01-31
NCT00716456 Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed “Acquired Resistance” to Erlotinib https://ClinicalTrials.gov/show/NCT00716456 Completed Memorial Sloan Kettering Cancer Center 2011-05-31
NCT00511485 Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03) https://ClinicalTrials.gov/show/NCT00511485 Completed Endocyte 2009-07-31
NCT00456716 Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma https://ClinicalTrials.gov/show/NCT00456716 Completed Swedish Medical Center 2008-12-31
NCT00430261 Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma https://ClinicalTrials.gov/show/NCT00430261 Completed Swedish Medical Center 2010-10-31
NCT00368992 S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT00368992 Completed National Cancer Institute (NCI) 2010-10-31
NCT00334815 Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery https://ClinicalTrials.gov/show/NCT00334815 Active, not recruiting National Cancer Institute (NCI) 2014-07-01
NCT00284141 Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma https://ClinicalTrials.gov/show/NCT00284141 Completed Sanofi 2008-07-31
NCT00198380 Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature https://ClinicalTrials.gov/show/NCT00198380 Completed Intergroupe Francophone de Cancerologie Thoracique 2008-12-31
NCT00137839 Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung https://ClinicalTrials.gov/show/NCT00137839 Completed Dana-Farber Cancer Institute 2008-11-30
NCT00126581 Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT00126581 Completed National Cancer Institute (NCI) 2010-06-30
NCT00118183 Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT00118183 Completed National Cancer Institute (NCI) 2007-04-30
NCT00118144 Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer https://ClinicalTrials.gov/show/NCT00118144 Completed National Cancer Institute (NCI) 2010-12-31
NCT00087412 S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT00087412 Completed National Cancer Institute (NCI) 2007-07-31
NCT00073398 Vaccine Treatment for Advanced Non-Small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT00073398 Completed Lumos Pharma 2012-11-30
NCT00049543 Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery https://ClinicalTrials.gov/show/NCT00049543 Completed National Cancer Institute (NCI) 2011-04-30
NCT00040794 Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT00040794 Completed National Cancer Institute (NCI) 2006-03-31
NCT00021060 Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT00021060 Completed National Cancer Institute (NCI) 2006-09-30
NCT00020709 Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery https://ClinicalTrials.gov/show/NCT00020709 Completed National Cancer Institute (NCI) 2007-02-28
NCT00005838 Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery https://ClinicalTrials.gov/show/NCT00005838 Completed National Cancer Institute (NCI) 2007-02-28
NCT00002852 Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT00002852 Completed National Cancer Institute (NCI) 2004-07-31
NCT00818441 Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung https://ClinicalTrials.gov/show/NCT00818441 Completed Pfizer 2012-04-27

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03059641 Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China https://ClinicalTrials.gov/show/NCT03059641 Completed Geneplus-Beijing Co. Ltd. 2019-12-31
NCT02975752 EGFRdelEx19 and KRAS Exon 2 Mutation Detection in EBUS-TBNA https://ClinicalTrials.gov/show/NCT02975752 Completed University Hospital, Essen 2016-06-30
NCT02810262 Association of Bone and Metabolic Parameters With Overall Survival in Patients With Bone Metastases From Adenocarcinoma Lung Cancer (POUMOS) https://ClinicalTrials.gov/show/NCT02810262 Recruiting Hospices Civils de Lyon 2019-12-31
NCT02616211 An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors https://ClinicalTrials.gov/show/NCT02616211 Active, not recruiting Mayo Clinic 2025-12-31
NCT02093000 A Study Examining Maintenance Bevacizumab (Avastin®) Monotherapy in Participants With Advanced Lung Adenocarcinoma https://ClinicalTrials.gov/show/NCT02093000 Completed Hoffmann-La Roche 2018-01-31
NCT04202614 Prognostic Role of Positron Emission Tomography and Computed Tomography Parameters in Stage I Lung Adenocarcinoma https://ClinicalTrials.gov/show/NCT04202614 Recruiting IRCCS San Raffaele 2020-01-02
NCT04165759 Prospective Radiological Study of HRCT to Predict Pathological Noninvasiveness in NSCLC https://ClinicalTrials.gov/show/NCT04165759 Recruiting Fudan University 2020-09-30
NCT04122833 Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study https://ClinicalTrials.gov/show/NCT04122833 Recruiting Konkuk University Medical Center 2020-09-30
NCT04086680 The Detection of EGFR Mutations in Liquid Based Cytology Samples https://ClinicalTrials.gov/show/NCT04086680 Completed Royal Cornwall Hospitals Trust 2020-02-24
NCT03940846 CT-based Radiomic Signature Can Identify Adenocarcinoma Lung Tumor Histology https://ClinicalTrials.gov/show/NCT03940846 Active, not recruiting Maastricht University 2020-10-31
NCT03896958 The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology) https://ClinicalTrials.gov/show/NCT03896958 Recruiting SpeciCare 2021-03-12
NCT03838588 The Tracking Molecular Evolution for NSCLC (T-MENC) Study https://ClinicalTrials.gov/show/NCT03838588 Recruiting Geneplus-Beijing Co. Ltd. 2021-12-31
NCT01014286 Lung Cancer Mutation Consortium Protocol https://ClinicalTrials.gov/show/NCT01014286 Active, not recruiting University of Colorado, Denver 2020-09-30
NCT04370860 Optimal EGFR TKIs Treatment Strategies for Lung Adenocarcinoma Harboring EGFR Exon 19 Deletion Variants https://ClinicalTrials.gov/show/NCT04370860 Recruiting National Taiwan University Hospital 2025-03-31

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT02127359 Whole-Exome Sequencing (WES) of Cancer Patients https://ClinicalTrials.gov/show/NCT02127359 Active, not recruiting Dana-Farber Cancer Institute 2017-04-30
NCT03922828 Lung Nodule Prospective Database https://ClinicalTrials.gov/show/NCT03922828 Recruiting Singapore General Hospital 2023-04-30
NCT03641105 Investigation of the Contents and Prognostic Values of Glucose Metabolism Molecules in Patients With Lung Adenocarcinoma https://ClinicalTrials.gov/show/NCT03641105 Active, not recruiting Shanghai Zhongshan Hospital 2019-03-01